<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00023946</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02407</org_study_id>
    <secondary_id>NCI-2012-02407</secondary_id>
    <secondary_id>CDR0000068878</secondary_id>
    <secondary_id>NCI-3656</secondary_id>
    <secondary_id>UCCRC-11045</secondary_id>
    <secondary_id>UC#11045A</secondary_id>
    <secondary_id>3656</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <secondary_id>N01CM62201</secondary_id>
    <nct_id>NCT00023946</nct_id>
  </id_info>
  <brief_title>BMS-247550 in Treating Patients With Liver or Gallbladder Cancer</brief_title>
  <official_title>A Phase II Trial Of The Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Hepatobiliary Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of BMS-247550 in treating patients who have liver&#xD;
      or gallbladder cancer. Drugs used in chemotherapy use different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the objective response rate of patients with hepatobiliary cancer treated with&#xD;
      BMS-247550.&#xD;
&#xD;
      II. Determine the toxicity of this drug in these patients. III. Determine the duration of&#xD;
      response, median and overall survival, and time to progression in patients treated with this&#xD;
      drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at&#xD;
      least 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 6 weeks until disease progression&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (partial or complete response) evaluated by RECIST</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>A 10% response rate precludes further study whereas a 25% response rate would indicate that further study is warranted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and extent of cytotoxic activity graded according to the NCI CTC Version 2.0</measure>
    <time_frame>Up to 8 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>From the first day of treatment until the date PD or death is first reported, assessed up to 8 years</time_frame>
    <description>Will also be evaluated using the Kaplan-Meier estimator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the time measurement criteria are met for CR/PR (whichever is first recorded) until the first date that PD is objectively documented, assessed up to 10 years</time_frame>
    <description>Will also be evaluated using the Kaplan-Meier estimator.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Adult Primary Cholangiocellular Carcinoma</condition>
  <condition>Adult Primary Hepatocellular Carcinoma</condition>
  <condition>Advanced Adult Primary Liver Cancer</condition>
  <condition>Cholangiocarcinoma of the Extrahepatic Bile Duct</condition>
  <condition>Cholangiocarcinoma of the Gallbladder</condition>
  <condition>Localized Extrahepatic Bile Duct Cancer</condition>
  <condition>Localized Gallbladder Cancer</condition>
  <condition>Localized Resectable Adult Primary Liver Cancer</condition>
  <condition>Localized Unresectable Adult Primary Liver Cancer</condition>
  <condition>Recurrent Adult Primary Liver Cancer</condition>
  <condition>Recurrent Extrahepatic Bile Duct Cancer</condition>
  <condition>Recurrent Gallbladder Cancer</condition>
  <condition>Unresectable Extrahepatic Bile Duct Cancer</condition>
  <condition>Unresectable Gallbladder Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (ixabepilone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ixabepilone)</arm_group_label>
    <other_name>BMS-247550</other_name>
    <other_name>epothilone B lactam</other_name>
    <other_name>Ixempra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ixabepilone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed locally advanced, metastatic, or recurrent&#xD;
             hepatobiliary cancer&#xD;
&#xD;
               -  Liver (hepatocellular)&#xD;
&#xD;
               -  Bile duct (cholangiocarcinoma)&#xD;
&#xD;
               -  Gallbladder&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  The following are not considered measurable lesions:&#xD;
&#xD;
                    -  Lesions seen on colonoscopic examination or barium studies&#xD;
&#xD;
                    -  Bone metastases&#xD;
&#xD;
                    -  CNS lesions&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No other uncontrolled concurrent illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No prior allergic hypersensitivity reaction attributed to compounds containing&#xD;
             Cremophor EL (e.g., paclitaxel or compounds of similar chemical or biological&#xD;
             composition to BMS-247550)&#xD;
&#xD;
          -  No other currently active malignancy except nonmelanoma skin cancer, carcinoma in situ&#xD;
             of the cervix, or cancer for which patient has completed therapy and is at less than&#xD;
             30% risk of relapse&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  No concurrent therapeutic radiotherapy&#xD;
&#xD;
          -  At least 30 days since prior investigational agents&#xD;
&#xD;
          -  At least 7 days since prior cimetidine&#xD;
&#xD;
          -  No concurrent cimetidine&#xD;
&#xD;
          -  No other concurrent commercial or investigational anticancer agents or therapies&#xD;
&#xD;
          -  No concurrent unconventional therapies, food, or vitamin supplements (e.g., St. John's&#xD;
             Wort)&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hedy Kindler</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epothilones</mesh_term>
    <mesh_term>Epothilone B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

